The targeted expression of transgenes is one of the principal goals of gene therapy, and it is particularly relevant for the treatment of brain tumors. In this study, we examined the effect of the overexpression of human gas1 (growth arrest specific 1) and human p53 cDNAs, both under the transcriptional control of a promoter of the human glial fibrillary acidic protein (gfa2), employing adenoviral expression vectors, in glioma cells. We showed that the targeted overexpression of gas1 and p53 (AdSGas1 and AdSp53, respectively) in rat glioma cells (C6) reduced the number of viable cells and induced apoptosis. Moreover, the adenovirally targeted expression of these genes also reduced tumor growth in vivo. Unexpectedly, there was no additive effect when both gas1 and p53 were simultaneously expressed in the same cells using a bicistronic adenoviral vector. We suggest that Gas1 does not act in combination with p53 in the C6 and U373 glioma cell lines, inducing apoptosis and cell cycle arrest. Our results indicate that the targeted expression of tumor suppressor genes (gas1 and p53) regulated by the gfa2 promoter, together with adenoviral vectors may provide an interesting approach for adjuvant selective glioma gene therapy.
Introduction
Gliomas are the most common primary tumors of the central nervous system (CNS), and glioblastoma multiforme is the most malignant type of these tumors. Despite maximum treatment efforts, the prognosis of patients with gliomas remains very poor, and the lifespan is less than 1 year after diagnosis. 1 Current therapy includes surgery, radiotherapy and chemotherapy. However, gliomas are highly refractory to conventional therapy due to the biological properties of the tumors, such as high infiltration into the brain parenchyma leading to recurrence of the tumor, and resistance to chemotherapy and radiotherapy. 2 Novel strategies of therapy for gliomas have been developed including gene therapy, virotherapy, adoptive immunotherapy, and vaccination studies. These therapeutic strategies have been translated into clinical trials. 3, 4 Unfortunately, to date, the results achieved from most clinical trials have not shown substantial therapeutic efficacy.
Growth arrest specific-1 (gas-1) is a pleiotropic GPI (glycosil-phosphatidylinositol)-linked protein. 5 There are reports indicating that Gas1-mediated growth arrest is p53-dependent, but that it is independent of the p53 transactivating function. 6 On the other hand, Gas1-induced apoptosis is p53-independent and it has been observed in interdigital cell death during development. 7 Gas1 prevents DNA synthesis by blocking the entry of cells into the S phase. 8 Recently, several reports have shown that Gas1 is involved in programmed cell death (apoptosis) in different types of cells. 7, 9, 10 Furthermore, we have shown that the targeted overexpression of gas1 induces apoptosis in retrovirally tranduced C6 cells and inhibits tumor growth in vivo.
11 Taken together, these results suggest that the expression of the proapoptotic gene gas1 could be a useful therapeutic tool in cancer gene therapy. Furthermore, p53 is a critical component in cell cycle regulation and apoptosis, and is a key participant in the development of gliomas. The expression of p53 has also been employed as an experimental approach to treat gliomas 12 and recent reports showed the relevance of reactivating p53 to induce tumor growth regression indicating that p53 is an important therapeutic target. 13, 14 Two major approaches have been explored in experimental gene targeting to the CNS. The first one is based on tropism-modified viral vectors that target specific cell populations, and the second is based on the transcriptional regulation of therapeutic genes using cell-type or inducible promoters. 15 Previously, we and other groups have shown that a 2.2 kilobases (kb) fragment of the human glial fibrillary acidic protein (GFAP) promoter (gfa2) is sufficient to regulate the targeted expression of different transgenes in astrocytes, glioma cell lines and primary astrocyte cultures. 11, [16] [17] [18] Importantly, glial-specificity transcription of the gfa2 promoter was preserved, independently of the gene transfer method employed 11, [19] [20] [21] and the gfa2 promoter has been used to study the role of glial cells in neurogenesis using transgenic mice. 22 In this study, we examined the effect of different adenoviral systems to target specifically the expression of both gas1 and p53 transgenes to glioma cells. We showed that the adenovirus-mediated overexpression of gas1 (AdSGas1) in rat glioma cells (C6) and human astrocytoma cells (U373) reduced the number of viable cells and induced apoptosis. In addition, we found that the adenovirally mediated targeted expression of gas1 and p53 significantly inhibited tumor growth in nude mice. However, the effect of a bicistronic adenoviral vector (AdSGi53), which expresses both human gas1 and human p53 regulated by the gfa2 promoter, was not different from AdSGas1 or AdSp53 monocistronic vectors, independently of the p53 status of the glioma cell line. We suggest that Gas1 and p53 do not act in combination, and that the Gas1 effect is not mediated by p53 in either C6 or U373 cell lines. Therefore, there are no additive or synergic effects of Gas1 and p53 inducing apoptosis in glioma cells. These results suggest that the targeted expression of gas1 and p53 driven by the gfa2 promoter from adenoviral vectors may provide an interesting approach for selective gene therapy against gliomas.
Materials and methods

Construction of adenoviral vectors
The adenoviral vectors were produced according to the pAdEasy System developed by Vogelstein and collaborators 23 (www.coloncancer.org). Briefly, the gfa2-LacZ and gfa2-gas1 fragments were excised from the pgfa2LacZ plasmid 16 and pgfa2gas1 vector 10 respectively, using BglII and cloned into the BglII restriction site of the pShuttle vector to produce the AdSLacZ and the AdSGas1 adenoviral vectors. The AdS53 vector was obtained as follows: human p53 cDNA was excised from the pC53-SN3 vector 24 with BamHI and cloned into the BamHI site of the pgfa2MCS plasmid (unpublished results) to obtain the pgfa2p53 plasmid. Subsequent to this procedure, the gfa2-p53 cassette was released with BglII and cloned into the pShuttle vector. On the other hand, to insure optimal expression levels of the second cistron of the AdSGi53 bicistronic vector, we inserted the gfa2-gas1 cassette, amplified by PCR from the pgfa2gas1 plasmid, into the EcoRI site of the pIRES vector (Promega, Madison, WI) so that the IRES sequence started within 100 nucleotides 25 following the termination codon of the human gas1 cDNA. Using NheI and SalI restriction endonucleases we released the gfa2Gas1IRES fragment from the pgGas1-IRES vector and inserted it into the XbaI/SalI restriction sites of the pShuttle vector to obtain pSgGi. We then placed the human p53 cDNA, amplified by PCR from the pC53-SN3 vector, near the 3 0 end (168 bp) of the IRES sequence. 26 The human p53 was cloned into the SalI site, that was filled in with Klenow and a BglII restriction site of the pSgGi vector obtaining the pSgfa2Gas1-IRES-p53 vector (pSgGi53). The cDNAs orientation was determined by restriction mapping and DNA sequencing. Recombinant virus was expanded in HEK293 cells and purified by ultracentrifugation on a cesium chloride gradient. Viral titers were determined by end point cytopathic effect assay on HEK293 cells and expressed as plaque-forming units per milliliter (pfu/ml).
Cell culture and adenoviral transduction C6 and U373 cells were grown in Dulbecco's modified Eagle F12 medium (DMEM-F12, Invitrogen, Carlsbad, CA) with 10% fetal calf serum (FCS, Invitrogen). HEK293 cells were obtained from ATCC and grown in DMEM-HG (Invitrogen) with 10% horse serum (Invitrogen), 2 mM L-glutamine (Sigma, St Louis, MO) and 110 mg/ml sodium pyruvate (Invitrogen) at 371C in a 5% CO 2 -95% air humidified atmosphere. The conditions for infections were as follows: cells were plated at a density of 4 Â 10 4 cells/well into 6-well plates. Twentyfour hours later, cells were infected with different recombinant adenoviral vectors. After 4 h in the presence of the adenovirus, the medium was changed for fresh medium. Cells were harvested at different time points according to the experiment.
RT-PCR and PCR assays RNA was extracted using the TriPure reagent (Roche, Mannhein, Germany). Five micrograms of total RNA were reverse-transcribed with M-MLV reverse transcriptase (Invitrogen), and 5 ml of the resulting cDNA amplified by PCR. The primer sets used to amplify gas1 were: sense 5 0 -CTGTGCCTGATGGCGCTGCTGC-3 0 and antisense 5 0 -GACTTGCTATTCTGTGCATC-3 0 . We amplified rat b-actin fragment using primers reported previously, 27 and the human b-actin fragment using the following primers: sense 5 0 -TGGCACCACACCTTCTACA-3 0 and antisense 5 0 -TCACGCACGATTTCCC-3 0 . On the other hand, the gfa2-gas1 fragment was amplified from the pgfa2gas1 vector using primers: sense 5 0 -GGAATTCCTGAGCTCCCACCT CCCTCT-3 0 and antisense 5 0 -GGAATTCCAGTGGGAC GCGGGCTCTC-3 0 , primers contain EcoRI linkers, for directional cloning. The cDNA of human p53 was amplified from the pC53-SN3 vector 24 using primers: sense 5 0 -GCCA TGGAGGAGCCGCAGTCAG-3 0 and antisense 5 0 -GAA GATCTTCTGGGAGGCTGTCAGTGGGGAAC-3 0 .
Cell viability
To determine the effect of adenovirus-mediated transgene expression on cell viability in C6 and U373 cells, we used the 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and the trypan blue exclusion assays. For MTT assay, cells were seeded in 96-well plates at a density of 2000 cells/well. Cells were infected with AdSLacZ or AdSGas1 with MOIs of 500 and 1000. Forty-eight hours later, the number of viable cells was assessed by measuring the conversion of the tetrazolium salt MTT into formazan. Cells were incubated with 25 mg of MTT in 50 ml of medium for 4 h at 371C, the medium was aspirated and the formazan crystals were dissolved in 150 ml of DMSO. Absorbance was read at 595 nm using an automated microplate reader (Bio-Rad). We also determined the number of viable cells 24, 48 and 72 h after infection using the trypan blue exclusion assay. Assays were performed in quadruplicate.
Cytotoxicity assay
Lactate dehydrogenase (LDH) activity was determined using the CytoTox 96 non-radioactive cytotoxicity assay kit (Promega).
Apoptosis assays
Forty-eight hours after transduction, we measured the percentage of apoptotic cells by flow cytometry (FACSCalibur, Becton-Dickinson, Franklin Lakes, NJ) using the Annexin-V-FLUOS staining kit (Roche). We also identified apoptotic cells by fluorescence microscopy. Briefly, cells were plated at densities of 2 Â 10 4 cells/well on 100 mm 2 coverslips in 24 wells plates and 48 h after transduction non fixed cells were processed using the Annexin-V-FLUOS staining kit (Roche) or using an in situ cell death detection kit based on the TdT-mediated dUTP nick end labeling (assay) (TUNEL) method according to the manufacturer's protocol (Roche). Cells were counterstained with 4,6-diamidino-2-phenylindole (DAPI) to reveal nuclei.
BrdU incorporation assay Cells were plated as described previously for the apoptosis assay, and incubated with 50 mM of BrdU for 6 h at 371C. Forty-eight hours after transduction, cells were analyzed for BrdU incorporation. We used a BrdU staining kit (Zymed) to reveal positive cells, according to the manufacturer's instructions. A total of 200-300 cells by coverslips were examined to determine the percentage of cells that incorporated BrdU.
Western blot analysis
Total protein was isolated using the TriPure reagent (Roche) according to the manufacturer's instructions. Fifty micrograms of total protein were separated on 8% SDS-PAGE gels and transferred into nitrocellulose membranes (Bio-Rad). Membranes were blocked for 1 h at room temperature in 5% nonfat milk/TBST (0.05% Tween-20, TBS) and incubated with the primary antibodies overnight at 41C. Blots were then incubated with a peroxidase-coupled secondary antibody followed by enhanced chemiluminescence detection (Perkin Elmer, Boston, MA), according to the manufacturer's instructions. The primary antibodies were anti-human p53 1:500 (Santa Cruz Biotechnology, Santa Cruz, CA), which recognizes both mutant and wild-type forms, anti-b galactosidase 1:500 (Promega) and anti-b actin 1:600. 28 
Subcutaneous tumors
Experiments were performed according to current Mexican legislation NOM-062-ZOO-1999 (SAGARPA), and in agreement with the Guide for the Care and Use of Laboratory Animals of National Institute of Health (NIH) and the internal (Cinvestav) guidelines. C6 cells 1 Â 10 6 were subcutaneously inoculated into the dorsal flank of 6-8 week-old nu/nu mice. When the tumors reached 4-5 mm (large axis), animals were divided into five groups and 3 days later were injected with 50 ml of PBS (control) or 1 Â 10 8 pfu/50 ml of adenovirus AdSLacZ, AdSGas1, AdS53 and AdSGi53 intratumorally every other day for a total of three injections. Tumor size was measured every second day for 21 days after the first viral injection. Tumor volume was calculated according to the formula V ¼ (D max )(D min ) 2 /(0.5), where D max and D min represent the large and small axes, respectively.
Immunohistochemical analysis
Mice were anesthetized with an overdose of pentobarbital (460 mg/kg) and killed 24 days after the first viral treatment. Mice were perfused with 0.9% saline solution followed by 4% p-formaldehyde in PBS (pH 7.4) and tumors were dissected out. For immunohistochemistry, 14-mm tissue sections were processed for dual immunofluorescence. An anti-human p53 monoclonal antibody (1:50, Santa Cruz Biotechnology) was revealed with a Texas Red streptavidin-conjugated secondary antibody (1:300 Vector Laboratories), and a polyclonal anti-Gas1 antibody, produced by ProSci Incorporated using the human specific peptide sequence DDGVPHPPRPGSGA (1:100), was used. The presence of Gas1 was revealed with a fluorescein streptavidin-conjugated secondary antibody (1:300 Vector Laboratories). Tissue sections were counterstained with DAPI.
Results
Construction and expression of monocistronic and bicistronic adenoviral vectors containing gas1 and p53 cDNAs, regulated by the gfa2 promoter We obtained replication-defective recombinant adenovirus using the AdEasy System. 29 Figure 1a shows a schematic representation of the adenoviral vectors used in this work. The AdSGas1 and AdS53 monocistronic adenoviral vectors express gas1 and p53 cDNAs driven by the gfa2 promoter, respectively. The AdSGi53 bicistronic adenovirus expresses both gas1 and p53 transgenes, regulated by the gfa2 promoter (Figure 1a) . The bicistronic adenoviral vector contains an internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV), which allows translation of both cDNAs from a single mRNA. 30 We also constructed AdSLacZ adenovirus that expresses b-galactosidase driven by the gfa2 promoter, as a control vector (Figure 1a) .
To determine transgene expression, we transduced C6 and U373 cells, rat and human glioma-derived lines respectively, with different adenoviral vectors. Figure 1b shows the expression of the LacZ protein in C6 and U373-cells transduced with the AdSLacZ vector. Human gas1 mRNA was identified in both AdGas1 and AdSGi53 glioma-transduced cells using RT-PCR assays (Figure 1c ).
Western-blot analysis was used to confirm the expression of human p53 protein in AdS53 and AdSGi53 C6 and U373-transduced cells (Figure 1d ). The human p53 protein was expressed exclusively in C6 cells that were transduced with AdS53 and AdSGi53 adenovirus. We also identified that the level of human p53 was higher in AdS53 (2.3 fold) and AdSGi53 (4.5 fold) U373-transduced cells compared with control cells. These results demonstrate the capacity of adenovirus to express transgenes driven by the gfa2 promoter.
Effects of the adenovirally mediated gene transfer of gas1 and p53 to glioma cell lines in cell viability, proliferation and cell-cycle progression We first compared the effect of gas1 expression on cell viability in AdSGas1-transduced cells with different multiplicity of infections (MOIs), using the MTT assay. Treatment with AdSGas1 employing 500 MOI and 1000 MOI significantly reduced the viability of C6 cells 48 h after transduction compared with the control vector AdSLacZ (Figure 2a) . However, in U373-transduced cells we only observed decreases of cell viability with 1000 MOI using the AdSGas1 vector (Figure 2b) . We determined that the efficiency of transduction of C6 and U373 cells was approximately 50 and 100% respectively, but the levels of GFAP expression were lower in U373 compared with C6 cells (as determined by immunocytochemistry, data not shown), therefore we used MOI 1000 in our assays to obtain a therapeutic effect. Moreover, other groups have used MOI as high as 2000-3000 to obtain therapeutic effects using adenovirus and tissue-specific promoters. 31, 32 To correlate the effect of gas1 expression on cell viability we measured the release of LDH from glioma-transduced cells, as an indicator of cell death. Figure 2c shows a significant increase of LDH release from AdSGas1-transduced C6 and U373 cells at 1000 MOI, compared with AdSLacZ. These results indicate that the reduction of cell viability was associated with an increase of cell death as determined by the LDH assay in glioma cell lines treated with adenovirus. To evaluate the effect of gas1 and p53 in C6 cells transduced with adenoviral vectors, we determined the viability of cells at different time points after transduction. We found that Gas1 and p53 decreased the number of viable C6 cells as a function of time. Forty eight hours after transduction AdSGas1 and AdS53 reduced the number of viable cells by 52.574.5 and 43.175.0%, respectively (Figure 2d ), compared with control. Also, AdSGi53 inhibits proliferation of C6 cells by as much 35.075.5%, 48 h after infection (Figure 2d ). However, we only found a significant cell reduction in AdSGas1 (26.278.6%) and AdSGi53 (21.2475.7%) U373-transduced cells compared with control vector AdSLacZ (Figure 2e ). We determined this effect for upto 72 h after transduction for each adenoviral vector tested. We next tested whether the decrease in cell proliferation results from a reduction in the proliferation rate or to an increase in apoptosis. To evaluate the rate of proliferation, we determined the number of cells that incorporated BrdU, as a direct measure of cells undergoing DNA synthesis at a given time. Figure 3a shows a representative BrdU immunocytochemistry of treated C6 cells, in which we can observe a decrease in the number of BrdU-positive cells (cells with dark nuclei) that overexpress gas1 and p53. When we determined the percentage of cells that incorporated BrdU, we found that AdSGas1, AdS53 and AdSGi53 groups incorporated 40.574.4, 47.674.5 and 45.478.5%, respectively less BrdU than the AdSLacZtreated group (Figure 3b ), but there was no significant difference between them. We also determined that AdSGas1, AdS53 and AdSGi53 inhibited the proliferation rate of U373 cell by 29.5712.9, 16.777.1 and 24.97 5.5% respectively, compared with control group (AdSLacZ) (Figure 3c ). These data indicate that both gas1 and p53 expression inhibits the G 1 -S transition of cell cycle in C6 cells, but in U373 cells only gas1 was capable of significantly inhibit cell-cycle progression, and that the targeted coexpression of gas1 and p53 using the bicistronic vector had the same effect on the proliferation rate in C6 and U373 cells as the monocistronic vectors.
Adenovirus-mediated Gas1 and p53 expression in C6 cells induce apoptosis
Several groups have shown that Gas1 is involved in cell death and apoptosis. 7, 33 To determine whether the decrease of cell proliferation and number of viable cells that express gas1 and p53 is related to apoptosis, we analyzed the translocation of phosphatidylserine to the external side of the cell membrane using Annexin V staining as an indicator of apoptosis by FACS analysis in C6 cells. Using Annexin V-conjugated FITC and propidium iodide (PI) staining, we found that the percentage of early-and late-apoptotic cells increased when cells were transduced with AdSGas1, AdS53 and AdSGi53 (13.5, 18.4 and 15.2% respectively), compared with and transduced with control vector (1.4% in AdSLacZ-transduced cells) (Figure 4a ). Using fluorescence microscopy, no positive staining to Annexin V was observed in AdSLacZ C6-transduced cells (data not shown), but we found positive staining in cells overexpressing gas1 and p53, or both (Figure 4b ). In addition, we used TUNEL staining to identify cells undergoing DNA fragmentation, as another marker of an apoptotic process. In Figure 4c we observe that AdSGas1, AdS53 and AdSGi53 transduced cells were positive for TUNEL staining. Therefore, these assays indicate that the reduction in the number of viable cells 48 and 72 h after viral transduction with gas1 and p53 transgenes (Figure 2 ) is related to both cell cycle inhibition and programmed cell death.
A GFAP promoter drives gas1 and p53 expression in vivo and suppresses xenograft tumor growth using adenoviral vectors To evaluate the effect of the targeted expression of gas1 and p53 in an in vivo glioma model using xenograft tumors, we subcutaneously established C6 tumors in nude mice, and treated them with the different adenoviral vectors. We injected C6 cells into the flanks of nude mice, and when the tumors reached 4-5 mm of longer axis, we admininistered the adenoviral vectors intratumorally every other day for a total of three injections. We monitored the size of the tumors for 24 days after the first injection. At the end of the experiment, mice were killed and tumors dissected out. The treatments with AdSGas1 or AdS53 resulted in 64.9717.4 and 59.57 26.1% suppression of tumor growth, which was significantly different compared with the untreated and LacZ groups, 21 days after the first injection ( Figure 5) . Unexpectedly, the group treated with AdSGi53, which expresses both gas1 and p53 from the same gfa2 promoter, showed a smaller inhibition of tumor growth (46.3715.9% compared with the untreated group), that is different from both the independent administration of Gas1 and p53. The tumor suppression effect using bicistronic adenovirus correlates with the effect on cell proliferation (Figure 2d ). We next confirmed gas1 and p53 transgene expressions in tumors by immunohisto- (Figure 6a ). In addition, we observed human p53-specific expression in tumors treated with AdS53 and AdSGi53 (Figure 6b ). Furthermore, we showed colocalization of Gas1 and p53 expression in AdSGi53-treated tumors (Figure 6c ). Taken together, our results show that tumor growth suppression results of both cell cycle arrest and apoptosis induced by the overexpression of gas1 and p53 in glioma cells.
In conclusion, our results demonstrate that AdSGas1 and AdS53 have tumor suppressor activity both in vitro and in an in vivo glioma model with transgenes driven by gfa2, a glial-specific promoter, and that the results of both growth arrest and apoptosis induced by the overexpression of gas1 and p53.
Discussion
We report that the effect of gas1 (AdSGas1) on cell viability and tumor growth inhibition was similar to the effect of p53 driven by the gfa2 promoter (AdS53). Taken together, these results confirm the role of gas1 as a tumor suppressor gene.
There is yet no complete description of the molecular mechanism by which Gas1 induces cell arrest and apoptosis. Lee and coworkers 34 reported that Gas1 antagonizes SHH (Sonic hedgehog) function in the dorsal somite. More recently, we 35 and subsequently others 36 reported the structural similarities between Gas1 and the GDNF family of coreceptors (GFR-a) and shown that Ret-mediated pathways may be altered by Gas1. 36 These data suggest that Gas1 may interfere in the GDNFmediated signaling, and there is evidence indicating that Ret-mediated signaling pathways may be altered by Gas1. 36 These new evidences may explain the reduction of cell proliferation and tumor growth suppression induced by Gas1 in our model. Previous results have shown that GDNF and Ret are highly expressed in C6 cells, 37, 38 and that GDNF exerts a powerful proliferative effect on them. 39 Therefore, we propose that the effects of GDNF on the proliferation of C6 cells is antagonized by the overexpression of gas1 and results in cell death (in preparation).
We cannot exclude at this point that the inhibition of GDNF signaling by Gas1 also results in autophagic cell death. Some reports indicate that the deprivation of GDNF from cells in culture induces autophagic cell death. [40] [41] [42] Using vital staining with acridine orange for the detection of autophagy, 43, 44 we found that C6 cells that overexpress gas1 show acidic vesicle organelles (AVO) in the cytoplasm, a characteristic of autophagic process (data no shown). These results suggest that Gas1 blocks GDNF-signaling pathways, and may induce autophagy in C6 cells. This is the first time that a link between Gas1 and autophagic cell death is proposed. More experiments are necessary to elucidate the relationship between Gas1 and GDNF in both apoptosis and autophagic cell death.
On the other hand, our results show that the coexpression of gas1 and p53 in the same cells using a bicistronic adenoviral vector has a similar effect both on cell proliferation and tumor growth as the individual expression of each one of these transgenes in the C6 glioma model. We suggest that Gas1 and p53 act independently and that the Gas1 effect is not mediated by p53, at least not in this model, in contrast with previous reports, in which different cell lines were used. 6, 45 These results are in agreement with previous reports which demonstrated that the ectopic expression of wild-type (wt) p53 in glioma cell lines with wild-type p53, such as C6 cells, 46 or mutant p53, like U373 cells 47 leads to cell death by apoptosis 48 or growth arrest, 46 depending on the final expression levels of p53, 49 as well as by the expression of other genes (that is, p21 and PUMA) involved in the p53 pathways. 50 In this study, we show that Gas1 does not require p53 to induce apoptosis and cycle arrest in glioma cells. Among the possible interpretations of the present data that deserve to be further explored there are: that a kinetic effect may participate, so that Gas1 and p53-induced intracellular signaling have different kinetics, and the faster system cancels out the effect of the other. Another possibility is related to interference of signal transduction pathways. As we have discussed, there is evidence indicating that Gas1 alters the GDNF intracellular signaling cascades, and that Gas1 inhibits the GDNFinduced activation of Akt 35, 36 ; (manuscript in preparation). One of the effects of Akt activation is to release NF-kB from IkB, thus allowing it to perform its transcriptional activities. 51 Although NF-kB activity is traditionally associated with cell survival pathways, it has been shown that it is required for efficient p53-induced apoptosis in some cellular systems. 52, 53 Thus, Gas1 could, by its inhibition of GDNF signaling, decrease the activity of NF-kB and thus impede the apoptotic process induced by p53. Finally, an extremely interesting hypothesis is that Ret acts as dependence receptor, 54 since it has been shown that Ret induces apoptosis in the absence of GDNF. 55 In the present situation, the absence of GDNF binding or activity would be due to Gas1 expression, and Ret will set the cell into an apoptotic process independent of p53.
Targeted gene expression aims at achieving the expression of therapeutic transgenes in specific and restricted cell populations, thus sparing all other cells of the unwanted effects of the gene product. This concept is particularly relevant for the treatment of cancer, because the principal objective of the therapy is to eliminate the tumor cells, and the optimal therapeutic outcome is to destroy cancer cells without harming healthy cells. 15 Some advantages of cell-specific promoters are that the transgene can be expressed, not only in the therapeutically appropriate cells, but also in a regulated manner and when necessary, for prolonged periods, compared with the use of viral promoters. However, occasionally one promoter may be active in different cell types, and its transcription can be downregulated by epigenetic processing. 56 Transcriptional regulation of transgene expression has been extensively used to express therapeutic transgenes in gliomas using the GFAP promoter. 10, 11, 18, [57] [58] [59] Reaching the goals of targeted gene expression will greatly increase the specificity and safety of gene therapy, thus getting us closer to the fulfillment of the expectations generated by this new branch of molecular medicine.
Gene therapy approaches for the treatment of cancer include the combination of the expression of a therapeutic transgene together with the administration of pharmacological agents, or the expression of more than one therapeutic transgene. There are several examples of successful coexpression of transgenes to increase their individual therapeutic efficacy, using both viral and non-viral systems. [60] [61] [62] [63] The success of these approaches will depend on the additive or synergistic effects of the transgenes used, the specific tumor, the efficiency of the gene delivery system, and case by case analysis will be necessary to determine the efficacy of the combinations.
In general, a gene therapy-corrective approach for gliomas involves the restoration of apoptotic pathways and/or the correction of cell cycle control. Thus, the targeted expression of gas1 using the gfa2 promoter to drive its expression is an interesting approach to treat gliomas, because Gas1 blocks the proliferative action of GDNF, which is implicated in glioma cell migration and proliferation. 39, 64 Also, it is reported that Gas1 antagonizes the Shh pathway, 34, 65 which is involved in brain tumor formation and tumor growth. 66, 67 Moreover, Gas1 inhibits cell proliferation and induces cell death (apoptosis and/or autophagy) even in the absence of active p53. Additionally, we also propose the targeted overexpression of p53 using the gfa2 promoter as an alternative treatment for gliomas, because p53 is the most common tumor suppressor gene inactivated in gliomas and it has a critical role in the progression of these tumors. Recent reports showed the relevance of p53 in tumor growth and indicated that reactivation of p53 induces tumor growth regression and cell death. 13, 14 Therefore, according to these and previous results we propose that the targeted expression of gas1 and p53 driven by the gfa2 promoter using adenovirus as the gene transfer system is an interesting adjuvant strategy for the selective gene therapy of gliomas.
